Kissei Pharmaceutical

4547.T

Matsumoto, Japan· Est. 1946

kissei.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

4547.T · Stock Price

JPY 4,370+215 (+5.17%)

Market Cap: $1.2B

Historical price data

Market Cap: $1.2BPipeline: 63 drugs (28 Phase 3)Patents: 20Founded: 1946Employees: 1,000-5,000HQ: Matsumoto, Japan

Sector Ranking#38 in Small Molecule Drugs

Overview

Kissei Pharmaceutical's mission is to contribute to global healthcare by developing and providing innovative, high-quality pharmaceutical products. The company has achieved a strong market position in Japan through its established expertise in urology and nephrology, supported by a portfolio of marketed products and a promising late-stage pipeline. Its strategy centers on deepening its specialization in core therapeutic areas while expanding its global footprint through strategic in-licensing and co-development partnerships. With a market capitalization of approximately $193.58 billion, Kissei possesses the financial strength to advance its R&D ambitions and pursue strategic opportunities.

UrologyNephrologyMetabolic DisordersGastrointestinalRare Diseases

Technology Platform

Integrated small-molecule drug development engine specializing in medicinal chemistry, clinical development, and formulation, with deep expertise in urology and nephrology.

Pipeline

63 drugs in pipeline28 in Phase 3

Drug	Indication	Stage
KAD-1229 + Placebo + Insulin	Type 2 Diabetes Mellitus	Approved
Avacopan, prednisolone and rituximab + Prednisolone and ritu...	ANCA Associated Vasculitis (AAV)	Approved
KLH-2109 + Leuprorelin	Uterine Fibroids (MeSH Heading: Leiomyoma)	Phase 3
KAD-1229	Type 2 Diabetes	Phase 3
KUC-7483 + Placebo + Tolterodine	Overactive Bladder	Phase 3

Funding History

IPOUndisclosedUndisclosedMar 15, 2002

Opportunities

Significant near-term growth from the launch of finerenone for diabetic kidney disease in Japan.

Expansion into rare diseases (e.g., FSGS, TGCT) offers high-value specialty market opportunities.

Strategic in-licensing provides a capital-efficient path to pipeline diversification and global reach.

Risk Factors

Revenue growth is heavily dependent on successful commercialization of key late-stage assets like finerenone.

The company faces ongoing pricing pressure in its core Japanese market from biennial NHI price revisions.

Reliance on partners for several pipeline programs introduces strategic and operational dependencies.

Competitive Landscape

Competes with large Japanese pharma (Astellas, Takeda) and global multinationals (Pfizer, Bayer) in urology and nephrology. Differentiates through deep specialty focus, strong KOL relationships in Japan, and integrated development/commercial capabilities. Faces intense competition in crowded therapeutic areas requiring superior data and execution.